# Septerna, Inc.: financial statements, quarterly

SEPN · Nasdaq · CIK 1984086 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sepn.md) · [Financials](/companies/sepn/financials.md) · [Filings](/companies/sepn/filings.md) · [Insiders](/companies/sepn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sepn/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-129274.md) | [0.1 d](/filings/0000950170-25-045745.md) | [0.3](/filings/0000950170-25-072619.md) | [0.4](/filings/0000950170-25-106551.md) | [0.2](/filings/0001193125-25-273375.md) | [0.2 d](/filings/0001193125-26-098507.md) | [0.2](/filings/0001193125-26-216759.md) | [0.1](/filings/0001193125-26-342353.md) | [21.5](/filings/0001193125-25-273375.md) | [24.1 d](/filings/0001193125-26-098507.md) | [26.5](/filings/0001193125-26-216759.md) | [26.7](/filings/0001193125-26-342353.md) |
| Research and development | $m | [9.3](/filings/0000950170-24-129274.md) | [10.3 d](/filings/0000950170-25-045745.md) | [13.2](/filings/0000950170-25-072619.md) | [15.0](/filings/0000950170-25-106551.md) | [17.8](/filings/0001193125-25-273375.md) | [19.3 d](/filings/0001193125-26-098507.md) | [19.3](/filings/0001193125-26-216759.md) | [22.2](/filings/0001193125-26-342353.md) | [24.3](/filings/0001193125-25-273375.md) | [31.9 d](/filings/0001193125-26-098507.md) | [29.5](/filings/0001193125-26-216759.md) | [35.1](/filings/0001193125-26-342353.md) |
| Operating income | $m | [(12.0)](/filings/0000950170-24-129274.md) | [34.3 d](/filings/0000950170-25-045745.md) | [(15.5)](/filings/0000950170-25-072619.md) | [(18.1)](/filings/0000950170-25-106551.md) | [(22.6)](/filings/0001193125-25-273375.md) | [(24.7) d](/filings/0001193125-26-098507.md) | [(25.9)](/filings/0001193125-26-216759.md) | [(29.0)](/filings/0001193125-26-342353.md) | [2.6](/filings/0001193125-25-273375.md) | [(16.0) d](/filings/0001193125-26-098507.md) | [(13.3)](/filings/0001193125-26-216759.md) | [(16.8)](/filings/0001193125-26-342353.md) |
| Income tax | $m | not reported | not reported | [0.1](/filings/0000950170-25-072619.md) | [0.1](/filings/0000950170-25-106551.md) | [(0.1)](/filings/0001193125-25-273375.md) | [(0.2) d](/filings/0001193125-26-098507.md) | [0.0](/filings/0000950170-25-072619.md) | [0.0](/filings/0001193125-26-342353.md) | [0.0](/filings/0001193125-25-273375.md) | [0.0 d](/filings/0001193125-26-098507.md) | [0.3](/filings/0001193125-26-216759.md) | [1.0](/filings/0001193125-26-342353.md) |
| Net income | $m | [(10.9)](/filings/0000950170-24-129274.md) | [34.9 d](/filings/0000950170-25-045745.md) | [(14.1)](/filings/0001193125-25-273375.md) | [(16.5)](/filings/0001193125-25-273375.md) | [(20.5)](/filings/0001193125-25-273375.md) | [(20.7) d](/filings/0001193125-26-098507.md) | [(21.5)](/filings/0001193125-26-342353.md) | [(24.8)](/filings/0001193125-26-342353.md) | [8.2](/filings/0001193125-25-273375.md) | [(10.7) d](/filings/0001193125-26-098507.md) | [(8.6)](/filings/0001193125-26-342353.md) | [(13.0)](/filings/0001193125-26-342353.md) |
| Diluted EPS | $ per share | [(5.45)](/filings/0000950170-24-129274.md) | not reported | [(6.35)](/filings/0000950170-25-072619.md) | [(7.03)](/filings/0000950170-25-106551.md) | [(8.40)](/filings/0001193125-25-273375.md) | not reported | [(0.49)](/filings/0001193125-26-216759.md) | [(0.56)](/filings/0001193125-26-342353.md) | [0.18](/filings/0001193125-25-273375.md) | not reported | [(0.19)](/filings/0001193125-26-216759.md) | [(0.29)](/filings/0001193125-26-342353.md) |
| Basic EPS | $ per share | [(5.45)](/filings/0000950170-24-129274.md) | not reported | [(6.35)](/filings/0000950170-25-072619.md) | [(7.03)](/filings/0000950170-25-106551.md) | [(8.40)](/filings/0001193125-25-273375.md) | not reported | [(0.49)](/filings/0001193125-26-216759.md) | [(0.56)](/filings/0001193125-26-342353.md) | [0.18](/filings/0001193125-25-273375.md) | not reported | [(0.19)](/filings/0001193125-26-216759.md) | [(0.29)](/filings/0001193125-26-342353.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [98.5](/filings/0000950170-24-129274.md) | [88.5](/filings/0000950170-25-045745.md) | [81.3](/filings/0000950170-25-072619.md) | [131](/filings/0000950170-25-106551.md) | [88.2](/filings/0001193125-25-273375.md) | [238](/filings/0001193125-26-098507.md) | [210](/filings/0001193125-26-216759.md) | [189](/filings/0001193125-26-342353.md) | [320](/filings/0001193125-25-273375.md) | [121](/filings/0001193125-26-342353.md) | [71.6](/filings/0001193125-26-216759.md) | [84.7](/filings/0001193125-26-342353.md) |
| Current assets | $m | not reported | [113](/filings/0000950170-25-045745.md) | not reported | not reported | [133](/filings/0000950170-24-129274.md) | [357](/filings/0001193125-26-098507.md) | [342](/filings/0000950170-25-072619.md) | [334](/filings/0000950170-25-106551.md) | [492](/filings/0001193125-25-273375.md) | [411](/filings/0001193125-26-342353.md) | [368](/filings/0001193125-26-216759.md) | [396](/filings/0001193125-26-342353.md) |
| Total assets | $m | not reported | [131](/filings/0000950170-25-045745.md) | not reported | not reported | [174](/filings/0000950170-24-129274.md) | [457](/filings/0001193125-26-098507.md) | [434](/filings/0000950170-25-072619.md) | [415](/filings/0000950170-25-106551.md) | [607](/filings/0001193125-25-273375.md) | [596](/filings/0001193125-26-342353.md) | [570](/filings/0001193125-26-216759.md) | [567](/filings/0001193125-26-342353.md) |
| Current liabilities | $m | not reported | [6.9](/filings/0000950170-25-045745.md) | not reported | not reported | [13.2](/filings/0000950170-24-129274.md) | [12.8](/filings/0001193125-26-098507.md) | [10.6](/filings/0000950170-25-072619.md) | [15.1](/filings/0000950170-25-106551.md) | [75.3](/filings/0001193125-25-273375.md) | [86.9](/filings/0001193125-26-342353.md) | [78.2](/filings/0001193125-26-216759.md) | [79.3](/filings/0001193125-26-342353.md) |
| Total liabilities | $m | not reported | [20.0](/filings/0000950170-25-045745.md) | not reported | not reported | [37.5](/filings/0000950170-24-129274.md) | [36.5](/filings/0001193125-26-098507.md) | [33.8](/filings/0000950170-25-072619.md) | [37.7](/filings/0000950170-25-106551.md) | [218](/filings/0001193125-25-273375.md) | [214](/filings/0001193125-26-342353.md) | [191](/filings/0001193125-26-216759.md) | [180](/filings/0001193125-26-342353.md) |
| Shareholders' equity | $m | [(73.8)](/filings/0000950170-24-129274.md) | [(38.4)](/filings/0001193125-26-098507.md) | [(51.9)](/filings/0001193125-25-273375.md) | [(67.8)](/filings/0001193125-25-273375.md) | [(87.4)](/filings/0001193125-25-273375.md) | [420](/filings/0001193125-26-342353.md) | [400](/filings/0001193125-26-342353.md) | [378](/filings/0001193125-26-342353.md) | [389](/filings/0001193125-25-273375.md) | [382](/filings/0001193125-26-342353.md) | [378](/filings/0001193125-26-342353.md) | [387](/filings/0001193125-26-342353.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.8) d](/filings/0000950170-25-045745.md) | [(16.7)](/filings/0000950170-25-072619.md) | [(13.0) d](/filings/0000950170-25-106551.md) | [(16.8) d](/filings/0001193125-25-273375.md) | [(21.0) d](/filings/0001193125-26-098507.md) | [(23.3)](/filings/0001193125-26-216759.md) | [(20.3) d](/filings/0001193125-26-342353.md) | [169 d](/filings/0001193125-25-273375.md) | [(15.0) d](/filings/0001193125-26-098507.md) | [(25.6)](/filings/0001193125-26-216759.md) | [(22.2) d](/filings/0001193125-26-342353.md) |
| Capital expenditure | $m | [1.2 d](/filings/0000950170-25-045745.md) | [0.8](/filings/0000950170-25-072619.md) | [0.1 d](/filings/0000950170-25-106551.md) | [0.6 d](/filings/0001193125-25-273375.md) | [0.6 d](/filings/0001193125-26-098507.md) | [0.4](/filings/0001193125-26-216759.md) | [0.1 d](/filings/0001193125-26-342353.md) | [0.0 d](/filings/0001193125-25-273375.md) | [0.1 d](/filings/0001193125-26-098507.md) | [0.8](/filings/0001193125-26-216759.md) | [0.0 d](/filings/0001193125-26-342353.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.0](/filings/0000950170-24-129274.md) | [2.2](/filings/0000950170-25-072619.md) | [2.3](/filings/0000950170-25-106551.md) | [2.4](/filings/0001193125-25-273375.md) | [43.9](/filings/0001193125-26-216759.md) | [44.2](/filings/0001193125-26-342353.md) | [45.6](/filings/0001193125-25-273375.md) | [44.8](/filings/0001193125-26-216759.md) | [45.0](/filings/0001193125-26-342353.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 46,676,947 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342353.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.